Evoke Pharma Inc represents strong values and embraces a corporate philosophy focused on innovation, patient care, and delivering breakthrough solutions in the pharmaceutical industry. With a steadfast commitment to research and development, Evoke Pharma strives to develop novel therapies that address unmet medical needs. By prioritizing collaboration and maintaining high ethical standards, the company aims to provide patients with effective treatment options. Evoke Pharma Inc consistently seeks to improve healthcare outcomes, enhance patient experiences, and create long-term value for shareholders.

Evoke Pharma Inc is primarily present in the United States.

Evoke Pharma Inc has achieved significant milestones. This pharmaceutical company specializes in developing innovative therapies for gastrointestinal disorders. Some of their notable accomplishments include the successful FDA approval of their product EVK-001, a nasal spray for the treatment of diabetic gastroparesis. Additionally, they have forged strategic partnerships with leading healthcare organizations to advance research and development efforts. Evoke Pharma Inc continues to make strides in improving patient care and addressing unmet medical needs in the field of gastrointestinal disorders.

Evoke Pharma Inc is a pharmaceutical company that specializes in developing innovative therapies for gastrointestinal disorders. Founded in 2007, the company is based in San Diego, California. Evoke Pharma is dedicated to improving patient outcomes by addressing unmet medical needs through its proprietary delivery technologies. With a strong focus on developing treatments for diabetic gastroparesis, a condition characterized by delayed gastric emptying, Evoke Pharma aims to provide effective solutions for patients worldwide. The company has made significant strides in advancing its product pipeline and collaborating with key partners to bring these much-needed therapies to the market.

The main competitors of Evoke Pharma Inc in the market include companies such as Johnson & Johnson, Pfizer, Novartis, GlaxoSmithKline, and AstraZeneca.

Evoke Pharma Inc is primarily active in the pharmaceutical industry.

The business model of Evoke Pharma Inc is focused on developing and commercializing innovative therapies for gastrointestinal diseases. The company primarily focuses on the development of EVK-001, a patented nasal spray formulation of metoclopramide, which is intended to treat symptoms associated with diabetic gastroparesis. Evoke Pharma Inc aims to provide a safe and effective treatment option to patients suffering from this condition. By leveraging its expertise in drug development and commercialization, Evoke Pharma Inc endeavors to improve the quality of life for individuals with gastrointestinal disorders.

Poměr Evoke Pharma P/E je -0,46.

Koeficient Evoke Pharma tržních hodnot je 0,13.

AlleAktien kvalitní skóre pro Evoke Pharma je 6/10.

očekávané Evoke Pharma obrat je 10,22 mil. USD.

očekávané Evoke Pharma zisk je -2,96 mil. USD.

Evoke Pharma Inc is a biopharmaceutical company focused on developing innovative solutions for unmet medical needs. The company specializes in the development and marketing of therapeutics to improve the lives of patients. The company has two main divisions: product development and marketing. The emphasis of product development is on developing new drugs, with a focus on gastrointestinal (GI) diseases. The company's goal is to create products that are more effective than current market offerings. One of the company's key products is Gimoti, which is used to treat nausea and vomiting in adults with gastroparesis. Gimoti is a dopamine receptor antagonist and the first oral spray approved by the FDA for gastroparesis treatment. Evoke Pharma Inc aims to strengthen the market position and awareness of Gimoti while expanding its product portfolio. The company collaborates with the FDA to explore additional uses for Gimoti and meet more medical needs. Evoke Pharma Inc follows an innovative business model, emphasizing collaboration with leading medical institutions and experts in the field of GI diseases. The company conducts extensive research and development to expand its product pipeline and strengthen its market position. It also employs a comprehensive marketing strategy, utilizing social media as an important sales channel to provide relevant and timely information to its target audience. Overall, Evoke Pharma Inc offers an innovative approach to the development and marketing of products for GI diseases. The company has released Gimoti, a promising product, and is expected to launch more products in the near future to improve the lives of patients with unmet medical needs.

Evoke Pharma vyplácí dividendu ve výši 0 USD rozdělenou do výplat během roku.

Dividenda pro Evoke Pharma momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti Evoke Pharma je US30049G1040.

WKN společnosti Evoke Pharma je A1W6DP.

Ticker společnosti Evoke Pharma je EVOK.

Během posledních 12 měsíců vyplatila společnost Evoke Pharma dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že Evoke Pharma vyplatí dividendu ve výši 0 USD.

Výnos z dividend společnosti Evoke Pharma aktuálně činí .

Evoke Pharma vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

Evoke Pharma vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 USD. To odpovídá dividendovému výnosu 0 %.

Evoke Pharma je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě Evoke Pharma ve výši 0 USD, zaznamenané 30. 12. 2024, měl jsi mít akcii ve svém portfoliu před ex-dnem 30. 12. 2024.

Poslední dividendy byly vyplaceny dne 30. 12. 2024.

V roce 2023 společností Evoke Pharma bylo vyplaceno 0 USD ve formě dividend.

Dividendy společnosti Evoke Pharma jsou vypláceny v USD.